These findings suggest that TP53-mutant KRAS-mutated NSCLC cells are more sensitive to WEE1 inhibitors than TP53 wild-type KRAS-mutated NSCLC cells. This evidence concerns the gene KRAS and non-small cell lung carcinoma.